Litcius/Paper detail

Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients

Katerina Laskari, Maria G. Tektonidou, Christina Katsiari, Panagiotis Athanassiou, Despoina Dimopoulou, Charalampos Gerodimos, Christina Salamaliki, Charalampos Papagoras, L. Settas, Dimitrios Vassilopoulos, Paraskevi V. Voulgari, Marina Zakalka, A. Georgiadis, G. Gkoni, Dimitrios Daoussis, Theodoros Dimitroulas, Chrisoula Iliou, I. Kallitsakis, E. Grika, C. Mavragani, Dimitrios Pikazis, John Raftakis, T. Sarikoudis, Nikolaos Kougkas, D. Soukera, Evangelos A. Theodorou, P. Tsatsani, Eleni Tsiakou, Panayiotis G. Vlachoyiannopoulos, G. Vosvotekas, Petros P. Sfikakis

2020Seminars in Arthritis and Rheumatism29 citationsDOI

Topics & Concepts

MedicineCanakinumabDiscontinuationRefractory (planetary science)Internal medicineCohortRetrospective cohort studyDiseasePediatricsAnakinraAstrobiologyPhysicsAutoimmune and Inflammatory Disorders ResearchInflammasome and immune disordersSpondyloarthritis Studies and Treatments
Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients | Litcius